SAMPLE — NOT LEGAL ADVICE. This response letter was generated automatically from publicly available analysis. It has NOT been reviewed by a licensed attorney and SHOULD NOT BE SENT to any party without substantial review and customization by qualified patent counsel. Use as a starting point only.

[Your Name]
[Your Title]
[Your Company]
[Street Address, City, State ZIP]

May 14, 2026

[Opposing Counsel Name]
[Firm Name]
[Address]

Re: U.S. Patent No. 11839689 — Response to Assertion of Infringement

Dear Counsel,

We acknowledge receipt of your correspondence asserting infringement of U.S. Patent No. 11839689 (the "11839689 Patent"). After preliminary review, we have substantial concerns about the validity, enforceability, and scope of the asserted claims, summarized below. We reserve all rights and defenses.

1. Subject Patent — Summary

A technical analysis of U.S. Patent 11,839,689 reveals it pertains to specific formulations of the prostate cancer drug enzalutamide, designed to improve its solubility and absorption. The patent is currently active and has been asserted in recent litigation.
Patent Summary:
• Title: Formulations of enzalutamide
• Assignee: Astellas Pharma Inc. and Medivation Prostate Therapeutics LLC
• Inventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, and Atsushi Kanbayashi.
• Filing Date: November 11, 2022
• Issue Date: December 12, 2023
• Abstract: The patent…

4. Litigation History of the Patent

Public records reflect that the 11839689 Patent has been the subject of the following litigation, which informs our view of the asserted claims and your client's enforcement posture:

• Astellas US LLC et al. v. Dr Reddys Laboratories Ltd — 3:26-cv-04101 · New Jersey District

Court · filed 2026-04-17 · Open

• Astellas Pharma Inc. et al. v. Various ANDA Filers — 2:24-cv-09403 · U.S. District Court for the District of New Jersey · Active

3. Request

In light of the foregoing, we request that your client (i) provide a detailed claim chart identifying each accused product or service and mapping every limitation of each asserted claim, (ii) identify any prior art known to your client, including any references cited during prosecution or reexamination, and (iii) substantiate the basis for any damages or licensing demand. We are prepared to discuss the matter further once we have received and reviewed the foregoing.

Sincerely,

[Your Name]

DISCLAIMER. This document is a machine-generated sample. The factual assertions, prior-art citations, and legal arguments above are AI-produced and may contain errors, omissions, or outdated information. Do not transmit this letter, in whole or in part, to any party. This is not legal advice; no attorney-client relationship is created by its existence. Consult a licensed patent attorney before responding to any patent-infringement assertion.

Generated May 14, 2026 by ihatepatenttrolls.com — sample only.